St. Renatus LLC Planning Phase 3 Trials for dental nasal anesthetic
St. Renatus LLC Planning Phase 3 TrialsSt. Renatus, LLC, which is dedicated to commercialize the world's first dental anesthetic administered through the nasal cavity, has joined SAFE-BioPharma Association. SAFE-BioPharma manages the SAFE-BioPharma® digital identity and signature standard, used throughout the biopharmaceutical industry to verify and manage digital identities involved in electronic transactions and to apply digital signatures to electronic documents.
"St. Renatus is one of a growing number of smaller companies that have decided to join the association so they can enjoy the cost and time-saving benefits of the SAFE-BioPharma standard"
As the anesthetic nasal mist enters U.S. Food and Drug Administration (FDA) Phase 3 clinical trials, St. Renatus will rely on SAFE-BioPharma digital signatures to accelerate and simplify handling electronic forms, contracts and other documents. By using the SAFE-BioPharma standard, the company will be able to eliminate paper records and securely provide identity verification.
"We view SAFE-BioPharma as the most practical and economical way to avoid the cost and time burden associated with paper. The big pharmaceutical companies have been using it for several years. We're pleased that the standard is available, and economical, to small companies as well," said Steven T. Merrick, St. Renatus' CEO.
SAFE-BioPharma digital signatures are uniquely linked to the individual's authenticated identity, and are more secure and legally binding than conventional electronic signatures. They are recognized by regulatory agencies throughout the U.S. and Europe.
"St. Renatus is one of a growing number of smaller companies that have decided to join the association so they can enjoy the cost and time-saving benefits of the SAFE-BioPharma standard," said Mollie Shields-Uehling, president and CEO, SAFE-BioPharma Association.